Digital therapeutics (DTx) are changing the way healthcare works. Unlike traditional apps or wellness tools, these products are designed to prevent, manage, or treat medical conditions using evidence-based interventions. Many of them go through rigorous clinical trials to prove they actually work—and that’s where the story usually gets exciting. A product demonstrates real results in improving patient health, investors cheer, and media headlines call it the “next big thing in healthcare.” 

But here’s the catch: proving clinical effectiveness is just the beginning. For a digital therapeutic to truly make an impact, it needs to be adopted by patients, covered by insurers, and integrated into the everyday routines of healthcare providers. And this is where the hard part begins. 

Imagine a digital therapeutic designed to help people manage chronic pain. It undergoes months of testing, shows statistically significant improvements in pain scores, and earns FDA clearance. On paper, this is a huge win. The science is solid, the product works, and the team has proof that it can change lives. 

Yet, many digital therapeutics struggle to translate these wins into real-world impact. Why? Because the healthcare ecosystem is complicated, and success is measured not just by outcomes in a controlled trial but by adoption in messy, everyday life. 

The adoption challenge

Even the most effective digital therapeutic can fail if nobody uses it. Adoption is one of the toughest hurdles for DTx companies because it requires changing behavior—both for patients and healthcare providers. 

For patients, using a digital therapeutic often means establishing a new habit. Unlike popping a pill, which is a quick, simple action, digital therapeutics usually require daily engagement: logging symptoms, following exercises, or participating in therapy modules. Many patients start strong but quickly lose motivation if they don’t see immediate results or if the app feels cumbersome. 

Healthcare providers face a different set of obstacles. Doctors and nurses are already pressed for time, and adding a digital tool to their workflow requires effort. They need to understand how it works, know which patients would benefit most, and have confidence that it actually improves outcomes. Without clear incentives, adoption can stall, leaving a clinically proven product underused. 

The reimbursement roadblock

Even if patients and providers are on board, there’s another big barrier: reimbursement. Unlike traditional medications, digital therapeutics often face unclear pathways for insurance coverage. Payers want evidence not only that a product works but also that it reduces overall costs or improves outcomes in a measurable way. 

Some digital therapeutics have managed to secure reimbursement codes, but many others are left in a gray area. This means patients may have to pay out of pocket, which limits accessibility and slows adoption. Without financial support from insurers, even the most effective digital therapeutic can remain under the radar. 

Behavior matters more than technology

Another crucial factor is patient behavior. A digital therapeutic can be brilliantly designed and clinically validated, but if it doesn’t fit seamlessly into someone’s life, it won’t stick. Engagement is key, and it’s influenced by many factors: 

• Ease of use: If the app is complicated or glitches often, users drop off quickly. 

• Motivation: Digital therapeutics that give immediate feedback or gamify progress often see better retention. 

• Integration into daily life: People are more likely to continue using a product if it fits naturally into their routines. 

This is why many digital therapeutics now focus as much on user experience as they do on clinical outcomes. A product that works in a trial but feels like a chore in real life is unlikely to make a lasting impact. 

Real-world evidence is key

One way digital therapeutics can overcome these challenges is by generating real-world evidence. Post-market studies, patient testimonials, and ongoing data collection can demonstrate how a product performs outside of clinical trials. This evidence can convince payers to cover the therapy, encourage healthcare providers to recommend it, and reassure patients that it’s worth their time. 

But collecting real-world evidence is expensive and time-consuming. It requires tracking usage, outcomes, and adherence over months or years, often with limited resources. For startups and even established companies, this is a major investment—but one that is increasingly necessary for survival. 

Partnerships can make or break success

Another factor that determines whether a digital therapeutic thrives after clinical validation is the strength of its partnerships. Collaborations with healthcare systems, insurers, pharmacies, and even patient advocacy groups can accelerate adoption and reimbursement. 

For example, a diabetes-focused DTx that partners with a major insurer can reach thousands of patients who otherwise might never try it. Similarly, integration with electronic health records (EHRs) makes it easier for doctors to prescribe and monitor the therapy. Partnerships don’t just expand reach—they also add credibility in a skeptical healthcare market. 

Why some products fail despite strong evidence

Despite all the effort, many digital therapeutics still fail to gain traction. This can happen for several reasons: 

• Poor timing: Entering the market before the healthcare system is ready can limit uptake. 

• High cost: Even with clinical evidence, expensive products struggle to justify coverage. 

• Low patient engagement: Without sustained use, outcomes may not match trial results. 

• Fragmented healthcare systems: Lack of integration with providers and insurers slows adoption. 

It’s not enough to have a great product. Digital therapeutics must navigate a complex ecosystem where human behavior, money, and systems all influence success. 

Proving clinical effectiveness is an essential milestone for digital therapeutics—but it’s far from the finish line. Adoption, reimbursement, patient behavior, and system integration all determine whether a product will make a meaningful impact. 

For companies in this space, the lesson is clear: winning in the clinic doesn’t guarantee success in the real world. The hard work comes next—convincing patients to engage, payers to cover, and providers to prescribe. 

In other words, the story of digital therapeutics isn’t just about what works in theory—it’s about what works in practice. And that’s where the real challenge—and opportunity—lies.